People · Operator
Named in public records as an officer, director or promoter · active 2017–2024 · Pharma, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| MCAL Therapeutics Inc. | — | Pharma | Series A | $6.3M | $34.8M | 2020 |
| SemantX Inc. | — | Other Technology | Pre-Seed | $500K | $21.2M | 2017 |
Charles O'Neill at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Charles O'Neill on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Foy | 1 | 3 |
| Christopher J Murphy | 1 | 3 |
| Thomas Gadek | 1 | 3 |
| Tom Gadek | 1 | 2 |
| Chris J. Murphy | 1 | 1 |
| Dan J. Albert | 1 | 1 |
| Tom J. Mather | 1 | 1 |
| Tanya Shnaydman | 1 | 1 |
| Lloyd Lee | 1 | 1 |
| Mark Eisner | 1 | 1 |
| KJ Lee | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.